Evidence map›Paper›PMID 25175597›Full record

ArticleBiomaterials2014

Macrophage embedded fibrin gels: an in vitro platform for assessing inflammation effects on implantable glucose sensors.

Matthew T Novak, Fan Yuan, William M Reichert

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Matthew T NovakDepartment of Biomedical Engineering, Duke University, 136 Hudson Hall, Box 90281, Durham, NC 27708, USA.
Fan YuanDepartment of Biomedical Engineering, Duke University, 136 Hudson Hall, Box 90281, Durham, NC 27708, USA.
William M ReichertDepartment of Biomedical Engineering, Duke University, 136 Hudson Hall, Box 90281, Durham, NC 27708, USA. Electronic address: reichert@duke.edu.
Duke University · US

Funding

University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
BIOSENSOR BIOCOMPATIBILITYR01DK054932 · NIDDK · DUKE UNIVERSITY · PI REICHERT, WILLIAM MONTGOMERY · 1999 to 2013
$4.2M
Biosensor BiocompatibilityR56DK054932 · NIDDK · DUKE UNIVERSITY · PI REICHERT, WILLIAM MONTGOMERY · 2008 to 2008
$258k
NIDDK NIH HHS DK 54932NIDDK NIH HHS R01 DK054932NIDDK NIH HHS R56 DK054932NIGMS NIH HHS GM T328555NIGMS NIH HHS T32 GM008555
6 · The paper itself

Abstract

The erroneous and unpredictable behavior of percutaneous glucose sensors just days following implantation has limited their clinical utility for diabetes management. Recent research has implicated the presence of adherent inflammatory cells as the key mitigating factor limiting sensor functionality in this period of days post-implantation. Here we present a novel in vitro platform to mimic the cell-embedded provisional matrix that forms adjacent to the sensor immediately after implantation for the focused investigation of the effects of early stage tissue response on sensor function. This biomimetic surrogate is formed by imbibing fibrin-based gels with physiological densities of inflammatory RAW 264.7 macrophages. When surrounding functional sensors, macrophage-embedded fibrin gels contribute to sensor signal declines that are similar in both shape and magnitude to those observed in previous whole blood and small animal studies. Signal decline in the presence of gels is both metabolically-mediated and sensitive to cell type and activation. Computational modeling of the experimental setup is also presented to validate the design by showing that the cellular glucose uptake parameters necessary to achieve such experimental declines align well with literature values. Together, these data suggest this in vitro provisional matrix surrogate may serve as an effective screening tool for testing the biocompatibility of future glucose sensor designs.

Indexed as

Biosensing Techniques3T3 CellsAnimalsBiocompatible MaterialsBlood GlucoseCell LineCells, ImmobilizedFibrinGelsInflammationMacrophagesMiceProstheses and ImplantsBiocompatible MaterialsBlood GlucoseFibrinGelsBiocompatibilityBiosensorsImmune responseInflammationMacrophage

Identifiers

PMID25175597
PMCPMC4164605
OpenAlexW2024872597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.